All (N = 100) | Inactivea (N = 64) | Activeb (N = 36) | p value | |
---|---|---|---|---|
Demographic characteristics | ||||
Age, mean (SD), years | 43 (14) | 42 (13) | 45 (14) | 0.175* |
Sex, women/men (%) | 93/7 (93/7) | 61/3 (95.3/4.7) | 32/4 (88.9/11.1) | 0.424† |
Education, median [IQR], years | 11 [5] | 11 [5] | 11 [9] | 0.754§ |
Current academic status, studying/not studying (%) | 12/88 (12/88) | 8/56 (12.5/87.5) | 4/32 (11.1/88.9) | 1† |
Current employment status, employed/unemployed (%) | 38/62 (38/62) | 27/37 (42.2/57.8) | 11/25 (30.6/69.4) | 0.349† |
Clinical characteristics | ||||
Disease duration, median [IQR], years | 8 [12] | 7 [12] | 10 [15] | 0.835§ |
Disease activity (SLEDAI), median [IQR], points | 2 [5] | 0 [1] | 6 [6] | < 0.001§ |
Accrued organ damage (SLICC-DI), median [IQR], points | 0 [1] | 0 [0] | 1 [2] | < 0.001§ |
Treatment compliance | ||||
Indicated-treatment compliance, yes/no (%) | 37/63 (37/63) | 27/37 (42.2/57.8) | 26/10 (72.2/27.8) | 0.152† |
Antimalarial indicated, yes/no (%) | 90/10 (90/10) | 59/5 (92.2/7.8) | 31/5 (86.1/13.9) | 0.532† |
Compliance, yes/no (%) | 56/34 (62.2/37.8) | 41/18 (69.5/30.5) | 15/16 (48.4/51.6) | 0.094|| |
Corticosteroid indicated, yes/no (%) | 85/15 (85/15) | 51/13 (79.7/20.3) | 34/2 (94.4/5.6) | 0.047|| |
Compliance, yes/no (%) | 60/25 (70.6/29.4) | 39/12 (76.5/23.5) | 21/13 (61.8/38.2) | 0.047‡ |
Immunosuppressant indicated, yes/no (%) | 45/55 (45/55) | 32/32 (50/50) | 13/23 (36.1/63.9) | 0.180|| |
Compliance, yes/no (%) | 18/27 (40/60) | 14/18 (43.7/56.3) | 4/9 (30.8/69.2) | 0.305|| |
Biological therapy indicated, yes/no (%) | 5/95 (5/95) | 3/61 (4.7/95.3) | 2/34 (5.6/94.4) | 1† |
Compliance, yes/no (%) | 0/5 (0/100) | 0/3 (0/100) | 0/2 (0/100) | – |
SLE flare-ups in the previous six months, yes/no (%) | 33/67 (33/67) | 17/47 (26.6/73.4) | 16/20 (44.4/55.6) | 0.068|| |
Merited hospitalisation, yes/no (%) | 1/32 (3/97) | 0/17 (0/100) | 1/15 (6.2/93.8) | 0.092† |